In this article
Introduction
The 2016 American Conference of Clinical Oncology (ASCO) is about to be held in Chicago as one of the most talked about academic conferences in the field of oncology. The new research and progress made by each ASCO conference are the focus of everyone’s attention.
CRITICS study
Marcel Verheij scholars from the Netherlands will soon announce the results of a phase III multi-center clinical study (CRITICS) from Europe at the 2016 ASCO conference. For gastric cancer patients who have undergone neoadjuvant , postoperative chemotherapy and postoperative chemoradiation are combined There was no significant difference in survival rate. The study will be presented orally at 8:00 am on June 6, 2016.
The study included a total of 788 patients with operable gastric cancer in the three countries of the Netherlands, Sweden and Denmark, all of whom underwent 3 cycles of ECC / EOC (eprubicin + cisplatin / oxaliplatin + capecitabine) Treatment, divided into chemotherapy group (n = 393, continue with another 3 cycles of ECC / EOC treatment) or chemotherapy group (n = 395,45 Gy + cisplatin + capecitabine) after operation, with an average follow-up of 50 months, mainly The study endpoint was overall survival (OS), and the secondary endpoints were disease-free survival (DFS), safety, and quality of life. The results showed that the 5-year OS in the chemotherapy group was 41.3%, and the 5-year OS in the chemotherapy group was 40.9%. There was no significant difference between the two groups. In terms of safety, it is mainly hematology and gastrointestinal adverse events.
The main cure for gastric cancer is radical surgical resection, but in Western countries, the long-term survival of advanced gastric cancer is poor (about 25%), and local recurrence occurs in about 80% of patients. Postoperative chemoradiation and perioperative chemotherapy have been shown to have survival benefits, but continued chemotherapy after neoadjuvant chemotherapy is inconclusive compared with postoperative chemoradiation.
The results of the CRITICS study suggest that for postoperative gastric cancer patients, there may be no significant difference in survival benefit between postoperative chemotherapy and postoperative chemoradiation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.